INTRODUCTION AND AIMS:
Living kidney donation requires evaluation of renal function. Recent KDIGO guidelines for living kidney donors suggest using the "best locally available" technique to evaluate GFR. That could result in using estimated GFR for some donors and measured GFR for others. However, there is a significant discrepancy between those techniques that could impact the decision to donate. METHODS: To evaluate the impact of GFR evaluation method on eligibility to donation we compared measured GFR with exogenous tracer to estimated GFR with 4 equations (CKD-EPI, MDRD, Full Age Spectrum, and Lund-Malmö). We conducted a multicentric study on 1743 French living kidney donors with enzymatic creatinine dosage and measured GFR. RESULTS: The CKD-EPI equation has the best overall performance (highest percentage of values within 10% or 30% of measured GFR, 48.8% and 94.4% respectively, lowest rmse, 16.2mL/min/1.73m 2 ). However, decision to donate is frequently based on a GFR threshold: 256 donors had an eGFR CKD-EPI higher than 90mL/min/1.73m 2 but an mGFR lower. Similarly 103 donors had an eGFR CKD-EPI higher than 80mL/min/1.73m 2 but an mGFR lower. The CKDEPI equation misclassified 14.7% and 6% of donors respectively. Alternatively, if decision to donate is based on an age-dependent threshold, we evaluated the ability of the CKDEPI equation to detect donors with an mGFR below the 2.5 th percentile of mGFR for age. Only 2% of the donors with an mGFR below the 2.5 th percentile of mGFR for age also had an eGFR CKD-EPI below the 2.5 th percentile for age. CONCLUSIONS: Even with the best overall performance of the CKDEPI equation, GFR estimation is not adapted to living kidney donors screening. Regardless on the acceptance criteria (fixed or age-dependent GFR threshold) measured GFR and estimated GFR give significantly different information that could change the decision to donate. It is well known, that lower PRA score is associated with higher transplant survival rate. Our research shows that sometimes a fall in PRA at the point of transplantation compared to the peak value may lead to an underestimation of the risk. METHODS: 287 recipients from the waiting list, with anti-HLA antibodies I, II or both classes (PRA>5%) were included in the study. Patients were screened periodically to identify PRA and the specificity of antibodies (identifying the intensity of the immunofluorescence of each antibody specificity). Of these recipients, 142 received a kidney transplant. At the point of the transplantation the patients had no donor specific antibodies. Cross-match (complement-dependent cytotoxicity test) was negative. HLAgenotyping of recipients was performed using the sequence specific primers method (A-, B-, DR-loci), antibodies were analysed using the Luminex platform (single antigen-bead based assay). Endpoints -graft loss and number of AMBR episodes. Poisson regression was used to assess the risk. Median follow up was 6.4 (IQR 3.5; 8.4) years. RESULTS: In the patients on the waiting list, the PRA, as well as MFI of specific circulating antibodies were not constant in time ( fig. 1) . Current PRA may decrease over time to 30-40% of the historical peak (maximum value) PRA. This is accompanied by a marked reduction in the MFI of some antibodies -sometimes below the lower threshold (but always higher than MFI of self-antigens!), which in this case was 1000. At times this may lead to an underestimation of the immunological risk.In univariate model, the increase in current PRA, increase in historical peak PRA and a decrease in DPRA (difference between peak and current PRA) was associated with an increased risk of ABMR (p<0.0001 each) and transplant loss (p<0.001 each) ( fig. 2) . In our opinion, DPRA is a very ambiguous measure. The inclusion of DPRA in the multivariate model of Poisson regression shows that an increase in current PRA is associated with increased risk of humoral rejection (p<0.001), but not with transplant survival (p¼0.17). Whilst historical peak PRA remains a significant factor for both humoral rejection of the transplant (p<0.001) and for its survival (p<0.001). CONCLUSIONS: In the selection of donor-recipient pairs it is necessary to consider the spectrum of antibodies at the point of the peak (highest) PRA score. A reduction in this indicator may in some cases be hiding antibodies, which are reactive to donor antigens or to certain epitopes. The using only current PRA value may lead to underestimation of risk.
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